XTL Biopharmaceuticals Effectuates ADR Ratio Change

HERZLIYA, Israel, October 4, 2012 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that following the announcement from September 24, 2012, its American Depositary Receipts ("ADRs") to ordinary shares ratio has changed today to 1:20 (1 ADR represents 20 ordinary shares). Please note that the ticker Symbol will temporarily change to XTLBD for 20 trading days beginning October 4th, after which it will revert back to XTLBY.

For additional information about the ADR ratio change, please contact Ms. Agness Moskovits of Bank of New York at: (212) 815 8223.

About XTL Biopharmaceuticals,Ltd. ("XTL")

XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.

XTL's lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world for the treatment of severe anemia.

XTL is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).

Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972-9-955-7080, Email: ir@xtlbio.com

SOURCE XTL Biopharmaceuticals Ltd